Know Your BRAF Status Before Treating Melanoma

BRAF status refers to the presence or absence of mutations in the BRAF gene, commonly found in melanoma, a serious form of skin cancer. Testing for BRAF mutations, especially the V600E mutation, plays a critical role in determining treatment options for patients with advanced or metastatic melanoma.

Why Test for BRAF Mutations?

About 40–60% of patients with advanced melanoma have a mutation in the BRAF gene. This mutation causes abnormal signaling that leads to rapid cancer cell growth. Identifying BRAF status allows doctors to tailor treatment strategies specifically to the genetic profile of the tumor.

Treatment if BRAF Mutation Is Present

If a BRAF mutation is positive, patients may benefit from targeted therapy, using drugs that specifically block abnormal BRAF signals:

Dabrafenib (BRAF inhibitor)
Trametinib (MEK inhibitor)

When used together, they help slow cancer progression and improve outcomes.

What If BRAF Mutation Is Negative?

If the BRAF test is negative, targeted therapy is unlikely to be effective. In these cases, immunotherapy becomes the mainstay of treatment. Options include: Nivolumab Pembrolizumab

Why BRAF Status Matters

Choose the most effective treatment
Avoid unnecessary medications
Improve survival rates
Provide personalized cancer care

Testing for BRAF status is a vital step in the treatment of advanced melanoma. It empowers doctors to select the most suitable therapy—whether it’s targeted therapy or immunotherapy—giving patients the best chance at effective disease control.

If you or a loved one is diagnosed with melanoma, talk to your doctor about BRAF testing to explore the full range of treatment options.